NeoGenomics, Inc.

Good day, ladies and gentlemen, and welcome to the Neogenomics second quarter 2022 earnings call. At this time, all participants have been placed on a listen-only mode, and the floor will be open for questions and comments after the presentation. It is now my pleasure to turn the floor over to your host, Lynn Petro. Ma'am, the floor is yours.

Thank you, Mike, and good morning. I'd like to welcome everyone to Neogenomics second quarter 2022 conference call. Joining me for this call from our Fort Myers headquarters are Bill Bonello, our Chief Financial Officer, Dr. David Sholovar, President of our Clinical Division, Vishal Sikri, President of our Pharma Services Division and President of Innovata, and Charlie Edson, our Director of Investor Relations. Joining on the call via phone are Dr. Shashi Kulkarni, President of Lab Operations and Chief Scientific Officer, and Chris Smith, our incoming Chief Executive Officer and member of our Board of Directors. Before we begin our prepared remarks, Charlie will discuss the forward-looking statements and non-GAAP measures used on this call.

This conference call includes forward-looking statements about our 2022 initiatives, 2022 financial outlook, growth opportunities, and anticipated operating results and performance. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those projected in such statements. Additional information regarding these risk factors appears under the heading forward-looking statements in the press release we issued this morning and in the risk factors section of our annual report on Form 10-K for the year ended December 31, 2021 that is filed with the Securities and Exchange Commission. The forward-looking statements made on this call speak only as of the original date of the call and we undertake no obligation to update or revise any of these statements. In addition, during the conference call, In order to provide greater transparency regarding our operating performance, we refer to certain non-GAAP financial measures that involve adjustments to GAAP results. The non-GAAP financial measures presented should not be considered to be an alternative to financial measures required by GAAP, should not be considered to be measures of liquidity, and are unlikely to be comparable to non-GAAP financial measures provided by other companies. Any non-GAAP financial measures referenced on this call are reconciled to the most directly comparable GAAP financial measure in a table available in the press release we issued this morning. Before turning the call back to Lynn, I want to let everyone know that we will be making a copy of our prepared remarks for this morning's call available on the investor relations section of our website shortly after the call is completed. We also want to let everyone know that we are going to limit the number of questions to one per person in order to give more people a chance to ask questions within the one hour that has been allotted for this call.